Skip to main content
Fig. 7 | Molecular Neurodegeneration

Fig. 7

From: Trehalose upregulates progranulin expression in human and mouse models of GRN haploinsufficiency: a novel therapeutic lead to treat frontotemporal dementia

Fig. 7

Oral trehalose administration increases PGRN and LC3-II in Grn+/− mouse brain. a Immunoblot of PGRN and LC3-II from brain lysates of treated Grn+/− animals. Grn+/+ and Grn−/− brain lysates included as controls for PGRN immunoreactivity. b PGRN was significantly increased in trehalose treated mice compared to vehicle (*P < 0.05) or sucrose (P = 0.1) treated mice by immunoblot. c Brain PGRN was significantly increased in trehalose treated mice compared to vehicle (**P < 0.01) or sucrose (**P < 0.01) treated mice by ELISA. d Immunoblot and ELISA PGRN levels were positively and significantly correlated. e LC3-II was significantly increased in trehalose treated mice compared to vehicle (*P = 0.05) or sucrose (*P < 0.05) treated mice by immunoblot. f PGRN and LC3-II were positively and significantly correlated across all animals by immunoblot. In b, c, and e, each measurement per animal is plotted with the mean ± SEM shown for each group. Statistical differences were calculated by one-way ANOVA followed by Tukey’s comparison post hoc test

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326